Author: Goodrum J
Publication Year: 2008
Citation: Int J Pharm Compounding 2008;12(4):286-292.
This is a response to the FDA’s attempt to halt the compounding of hormone preparations containing estriol. The author explains the background to this, which was primarily instigated by the pharmaceutical company Wyeth (manufacturer of Prempro). Estriol has been used clinically for decades without adverse effects when dosed appropriately, and is widely available in Europe. An explanation of actions being taken by the International Association of Compounding Pharmacists to reverse the FDA’s ban is given.